Scadenza: 5 March 2021
Scadenze successive:
Online submission May 26, 2021
Online submission with digital signatures of the PI and Legal Representative June 9, 2021
Topic:
All proposed research plans must have a clear objective that is consistent with the AIRC mission and will likely lead to advances in cancer biology, prevention, monitoring, diagnosis, or treatment of tumors in the near term.
Research plans should fall into one of the following research areas:
• Angiogenesis • Cancer genetics • Cancer stem cells • Cell adhesion, migration, invasion and metastasis • Cell cycle control and cell division • Cell death and apoptosis • Chemotherapy • Computational biology • Control of gene expression and epigenetics • Diagnosis • DNA damage and repair • Epidemiology and prevention • Gene therapy • Hormone therapy • Imaging • Immunotherapy • Infection, inflammation and cancer • Metabolism • Prognosis • Radiobiology and radiotherapy • Resistance to therapy • Signal transduction and intracellular trafficking • Structural biology • Targeted therapy and new therapeutics • Tumor immunology • Tumor microenvironment
Ente finanziatore:
Airc Foundation
Budget complessivo:
Up to 200.000 € /year
Duration of the project: 5 years
Who can participate:
Applicants can be of any nationality and are expected to have operated to the highest standards of integrity during their whole career. PIs must be involved in the project for at least 70% of their time and must be working in the Hosting Institution in Italy for at least 70% of their time during the funding period.
To be eligible for this reintegration grant, applicants must meet the following eligibility criteria:
Have a significant experience in a competitive laboratory outside of Italy. Applicants must not have been back in Italy for more than 12 months at the time of the presubmission application’s deadline.
Have a strong track record, including at least 2 primary research papers as first/co-first, last/co-last or corresponding/co-corresponding author
Applicants should be 35 years old or younger by the time of the pre-submission application’s deadline
Partnership: Not Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
All proposed research plans must have a clear objective that is consistent with the AIRC mission and will likely lead to advances in cancer biology, prevention, monitoring, diagnosis, or treatment of tumors in the near term.
Research plans should fall into one of the following research areas:
• Angiogenesis • Cancer genetics • Cancer stem cells • Cell adhesion, migration, invasion and metastasis • Cell cycle control and cell division • Cell death and apoptosis • Chemotherapy • Computational biology • Control of gene expression and epigenetics • Diagnosis • DNA damage and repair • Epidemiology and prevention • Gene therapy • Hormone therapy • Imaging • Immunotherapy • Infection, inflammation and cancer • Metabolism • Prognosis • Radiobiology and radiotherapy • Resistance to therapy • Signal transduction and intracellular trafficking • Structural biology • Targeted therapy and new therapeutics • Tumor immunology • Tumor microenvironment
Who can participate:
Applicants can be of any nationality and are expected to have operated to the highest standards of integrity during their whole career. PIs must be involved in the project for at least 70% of their time and must be working in the Hosting Institution in Italy for at least 70% of their time during the funding period.
To be eligible for this reintegration grant, applicants must meet the following eligibility criteria:
Have a significant experience in a competitive laboratory outside of Italy. Applicants must not have been back in Italy for more than 12 months at the time of the presubmission application’s deadline.
Have a strong track record, including at least 2 primary research papers as first/co-first, last/co-last or corresponding/co-corresponding author
Applicants should be 35 years old or younger by the time of the pre-submission application’s deadline
Programme:
Consortium: Not required
Status: Open
Total budget:
Up to 200.000 € /year
Funding rate:
100%
